原子能机构支持成员国生产靶向α治疗放射性药物的活动

IF 3.6 4区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear medicine and biology Pub Date : 2025-03-03 DOI:10.1016/j.nucmedbio.2025.109008

A.R. Jalilian , J. Kleynhans , P. Bouziotis , F. Bruchertseifer , S. Chakraborty , E. De Blois , M. Denecke , U. Elboga , M. Gizawy , C. Horak , J. Jang , A. Korde , A. Majkowska-Pilip , A. Mdlophane , B. Ocampo-Garcia , S.V. Selivanova , V. Starovoitova , W. Wojdowska , J.R. Zeevaart , V. Radchenko

{"title":"原子能机构支持成员国生产靶向α治疗放射性药物的活动","authors":"A.R. Jalilian , J. Kleynhans , P. Bouziotis , F. Bruchertseifer , S. Chakraborty , E. De Blois , M. Denecke , U. Elboga , M. Gizawy , C. Horak , J. Jang , A. Korde , A. Majkowska-Pilip , A. Mdlophane , B. Ocampo-Garcia , S.V. Selivanova , V. Starovoitova , W. Wojdowska , J.R. Zeevaart , V. Radchenko","doi":"10.1016/j.nucmedbio.2025.109008","DOIUrl":null,"url":null,"abstract":"<div><div>Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on <sup>225</sup>Ac-radiopharmaceuticals.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 109008"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals\",\"authors\":\"A.R. Jalilian , J. Kleynhans , P. Bouziotis , F. Bruchertseifer , S. Chakraborty , E. De Blois , M. Denecke , U. Elboga , M. Gizawy , C. Horak , J. Jang , A. Korde , A. Majkowska-Pilip , A. Mdlophane , B. Ocampo-Garcia , S.V. Selivanova , V. Starovoitova , W. Wojdowska , J.R. Zeevaart , V. Radchenko\",\"doi\":\"10.1016/j.nucmedbio.2025.109008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on <sup>225</sup>Ac-radiopharmaceuticals.</div></div>\",\"PeriodicalId\":19363,\"journal\":{\"name\":\"Nuclear medicine and biology\",\"volume\":\"144 \",\"pages\":\"Article 109008\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0969805125000174\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805125000174","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

由于国际原子能机构（IAEA）成员国对实施靶向放射性核素治疗（TRT）的兴趣日益浓厚，对α -发射放射性核素和放射性药物的需求是巨大的。作为和平应用放射性核素的国际平台，原子能机构一直在通过技术会议、讲习班、出版物和会议支助、原子能机构协调研究项目（CRP）和技术合作方案（TC）开展若干活动，重点关注α发射器和放射性药物的生产和质量控制以及该领域的能力建设。本文综述了国际原子能机构在用于靶向α治疗（TAT）的α发射器放射性药物的生产和质量控制方面的活动，以及未来步骤的路线图，包括但不限于正在进行的225ac放射性药物CRP。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals

查看原文本刊更多论文

IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals

Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on ²²⁵Ac-radiopharmaceuticals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nuclear medicine and biology 医学-核医学

CiteScore

6.00

自引率

9.70%

发文量

479

审稿时长

51 days

期刊介绍： Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.